Literature DB >> 16990692

Preoperative pharmacological management of phaeochromocytoma.

A N A van der Horst-Schrivers1, M N Kerstens, B H R Wolffenbuttel.   

Abstract

Phaeochromocytoma is a rare catecholamine-secreting neuroendocrine tumour with a high cardiovascular morbidity and mortality if left untreated. Surgical resection is the only curative therapy. During surgery there is a high risk of massive release of catecholamines, which can result in potentially fatal hypertensive crises and cardiac arrhythmias. Administration of vasoactive drugs such as (non)selective alpha- and beta-antagonists and calcium channel blocking agents have reduced the operation risk. Guidelines for the preoperative medical management of the patient with a phaeochromocytoma are mainly based on retrospective studies and case reports. We reviewed the relevant literature on this subject. In addition, we compared the several preoperative treatment protocols of the eight university medical centres in the Netherlands.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16990692

Source DB:  PubMed          Journal:  Neth J Med        ISSN: 0300-2977            Impact factor:   1.422


  20 in total

1.  Pheochromocytoma multisystem crisis successfully treated by emergency surgery: report of a case.

Authors:  Naotaka Uchida; Kiyosuke Ishiguro; Takako Suda; Motonobu Nishimura
Journal:  Surg Today       Date:  2010-09-25       Impact factor: 2.549

2.  Selective α1-adrenoceptor antagonist (controlled release tablets) in preoperative management of pheochromocytoma.

Authors:  Yu Zhu; Hong-chao He; Ting-wei Su; Yu-xuan Wu; Wei-qing Wang; Ju-ping Zhao; Zhoujun Shen; Chong-yu Zhang; Wen-bin Rui; Wen-long Zhou; Fu-kang Sun; Guang Ning
Journal:  Endocrine       Date:  2010-07-18       Impact factor: 3.633

Review 3.  From Diagnosis to Therapy-PET Imaging for Pheochromocytomas and Paragangliomas.

Authors:  Hiren V Patel; Arnav Srivastava; Murray D Becker; Toni Beninato; Amanda M Laird; Eric A Singer
Journal:  Curr Urol Rep       Date:  2021-01-06       Impact factor: 3.092

4.  Pheochromocytoma - update on disease management.

Authors:  Roland Därr; Jacques W M Lenders; Lorenz C Hofbauer; Bernd Naumann; Stefan R Bornstein; Graeme Eisenhofer
Journal:  Ther Adv Endocrinol Metab       Date:  2012-02       Impact factor: 3.565

Review 5.  Evaluation and Management of Stage 2 Hypertension in Pediatric Patients.

Authors:  Yosuke Miyashita; Coral Hanevold
Journal:  Curr Hypertens Rep       Date:  2018-07-06       Impact factor: 5.369

Review 6.  Therapy of acute hypertension in hospitalized children and adolescents.

Authors:  Tennille N Webb; Ibrahim F Shatat; Yosuke Miyashita
Journal:  Curr Hypertens Rep       Date:  2014-04       Impact factor: 5.369

7.  Nonfunctioning benign cardiac pheochromocytoma.

Authors:  Qingbao Li; Quanxin Fan; Decai Li; Haizhou Zhang
Journal:  J Cancer Res Clin Oncol       Date:  2008-06-19       Impact factor: 4.553

8.  Are patients with hormonally functional phaeochromocytoma and paraganglioma initially receiving a proper adrenoceptor blockade? A retrospective cohort study.

Authors:  Henrique Vara Luiz; Mary Jane Tanchee; Maria G Pavlatou; Run Yu; Joan Nambuba; Katherine Wolf; Tamara Prodanov; Robert Wesley; Karen Adams; Tito Fojo; Karel Pacak
Journal:  Clin Endocrinol (Oxf)       Date:  2016-04-15       Impact factor: 3.478

9.  Degree of catecholamine hypersecretion is the most important determinant of intra-operative hemodynamic outcomes in pheochromocytoma.

Authors:  C K Kramer; C B Leitão; M J Azevedo; L H Canani; A L Maia; M Czepielewski; A Paggi; T C Rodrigues; S P Silveiro; R Friedman; J L Gross
Journal:  J Endocrinol Invest       Date:  2009-03       Impact factor: 4.256

10.  Molecular docking study of catecholamines and [4-(propan-2-yl) phenyl]carbamic acid with tyrosine hydroxylase.

Authors:  Zahida Parveen; Muhammad Sulaman Nawaz; Shazi Shakil; Nigel H Greig; Mohammad A Kamal
Journal:  CNS Neurol Disord Drug Targets       Date:  2012-06-01       Impact factor: 4.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.